ARF suppresses tumor angiogenesis through translational control of VEGFA mRNA

Cancer Research

Volumn 70, Issue 11, 2010, Pages 4749-4758

  Kawagishi, Hiroyuki ^a   Nakamura, Hideaki ^a   Maruyama, Mitsuo ^a   Mizutani, Shuki ^b   Sugimoto, Kazushi ^c   Takagi, Masatoshi ^b   Sugimoto, Masataka ^a  

^a NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^c MIE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; MESSENGER RNA; NUCLEOPHOSMIN; PROTEIN P19 ARF; PROTEIN P53; UNCLASSIFIED DRUG; VASCULOTROPIN A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; COLON CARCINOMA; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MICROVASCULATURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; RNA INTERFERENCE; TRANSLATION REGULATION; TUMOR SUPPRESSOR GENE; TUMOR VASCULARIZATION;

ANIMALS; CELL NUCLEOLUS; CELL TRANSFORMATION, NEOPLASTIC; COLONIC NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; NEOVASCULARIZATION, PATHOLOGIC; NIH 3T3 CELLS; NUCLEAR PROTEINS; PROTEIN BIOSYNTHESIS; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEIN P14ARF; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77953168825     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-0368     Document Type: Article

References (48)

1. Quelle DE, Zindy F, Ashmun RA, Sherr CJ. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 1995;83:993-1000.
2. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993; 366:704-707
3. Sherr CJ. The INK4a/ARF network in tumour suppression. Nat Rev Mol Cell Biol 2001;2:731-737
4. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 1997;88:593-602.
5. Zindy F, Eischen CM, Randle DH, et al. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev 1998;12:2424-2433 (Pubitemid 28371361)
6. de Stanchina E, McCurrach ME, Zindy F, et al. E1A signaling to p53 involves the p19(ARF) tumor suppressor. Genes Dev 1998;12: 2434-2442 (Pubitemid 28371362)
7. Roussel MF. The INK4 family of cell cycle inhibitors in cancer. Oncogene 1999;18:5311-5317
8. Weber JD, Taylor LJ, Roussel MF, Sherr CJ, Bar-Sagi D. Nucleolar Arf sequesters Mdm2 and activates p53. Nat Cell Biol 1999;1:20-26 (Pubitemid 129495005)
9. Honda R, Yasuda H. Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53. EMBO J 1999;18:22-27
10. Bates S, Vousden KH. Mechanisms of p53-mediated apoptosis. Cell Mol Life Sci 1999;55:28-37.
11. Kamijo T, Bodner S, van de KE, Randle DH, Sherr CJ. Tumor spectrum in ARF-deficient mice. Cancer Res 1999;59:2217-2222
12. Weber JD, Jeffers JR, Rehg JE, et al. p53-independent functions of the p19(ARF) tumor suppressor. Genes Dev 2000;14:2358-2365
13. Sugimoto M, Kuo ML, Roussel MF, Sherr CJ. Nucleolar Arf tumor suppressor inhibits ribosomal RNA processing. Mol Cell 2003;11: 415-424
14. Bertwistle D, Sugimoto M, Sherr CJ. Physical and functional interactions of the Arf tumor suppressor protein with nucleophosmin/B23. Mol Cell Biol 2004;24:985-996
15. Itahana K, Bhat KP, Jin A, et al. Tumor suppressor ARF degrades B23, a nucleolar protein involved in ribosome biogenesis and cell proliferation. Mol Cell 2003;12:1151-1164
16. Forsythe JA, Jiang BH, Iyer NV, et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996;16:4604-4613 (Pubitemid 26272112)
17. Maxwell PH, Dachs GU, Gleadle JM, et al. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci U S A 1997; 94:8104-8109
18. Fatyol K, Szalay AA. The p14ARF tumor suppressor protein facilitates nucleolar sequestration of hypoxia-inducible factor-1α (HIF-1α) and inhibits HIF-1-mediated transcription. J Biol Chem 2001; 276:28421-28429
19. Gibson SL, Dai CY, Lee HW, et al. Inhibition of colon tumor progression and angiogenesis by the Ink4a/Arf locus. Cancer Res 2003;63: 742-746
20. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997;18:4-25.
21. Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology 2005;69 Suppl 3:4-10.
22. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003;3:401-410
23. Akiri G, Nahari D, Finkelstein Y, Le SY, Elroy-Stein O, Levi BZ. Regulation of vascular endothelial growth factor (VEGF) expression is mediated by internal initiation of translation and alternative initiation of transcription. Oncogene 1998;17:227-236 (Pubitemid 28371896)
24. Bornes S, Boulard M, Hieblot C, et al. Control of the vascular endothelial growth factor internal ribosome entry site (IRES) activity and translation initiation by alternatively spliced coding sequences. J Biol Chem 2004;279:18717-18726
25. Bornes S, Prado-Lourenco L, Bastide A, et al. Translational induction of VEGF internal ribosome entry site elements during the early response to ischemic stress. Circ Res 2007;100:305-308
26. Quelle DE, Cheng M, Ashmun RA, Sherr CJ. Cancer-associated mutations at the INK4a locus cancel cell cycle arrest by p16INK4a but not by the alternative reading frame protein p19ARF. Proc Natl Acad Sci U S A 1997;94:669-673 (Pubitemid 127651656)
27. Kuo ML, den Besten W, Sherr CJ. N-terminal polyubiquitination of the ARF tumor suppressor, a natural lysine-less protein. Cell Cycle 2004;3:1367-1369 (Pubitemid 40310668)
28. Gerlitz G, Jagus R, Elroy-Stein O. Phosphorylation of initiation factor-2 α is required for activation of internal translation initiation during cell differentiation. Eur J Biochem 2002;269:2810-2819
29. Kawagishi H, Wakoh T, Uno H, et al. Hzf regulates adipogenesis through translational control of C/EBPα. EMBO J 2008;27: 1481-1490
30. Zhang L, Yu D, Hu M, et al. Wild-type p53 suppresses angiogenesis in human leiomyosarcoma and synovial sarcoma by transcriptional suppression of vascular endothelial growth factor expression. Cancer Res 2000;60:3655-3661 (Pubitemid 30482190)
31. Brady SN, Yu Y, Maggi LB, Jr., Weber JD. ARF impedes NPM/B23 shuttling in an Mdm2-sensitive tumor suppressor pathway. Mol Cell Biol 2004;24:9327-9338
32. Korgaonkar C, Hagen J, Tompkins V, et al. Nucleophosmin (B23) targets ARF to nucleoli and inhibits its function. Mol Cell Biol 2005; 25:1258-1271
33. Ferrara N. VEGF as a therapeutic target in cancer. Oncology 2005;69 Suppl 3:11-16
34. Willett CG, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004;10:145-147
35. Ray PS, Fox PL. A post-transcriptional pathway represses monocyte VEGF-A expression and angiogenic activity. EMBO J 2007;26: 3360-3372
36. Karaa ZS, Iacovoni JS, Bastide A, Lacazette E, Touriol C, Prats H. The VEGF IRESes are differentially susceptible to translation inhibition by miR-16. RNA 2009;15:249-254
37. Ray PS, Jia J, Yao P, Majumder M, Hatzoglou M, Fox PL. A stress-responsive RNA switch regulates VEGFA expression. Nature 2009; 457:915-919
38. Ruggero D, Grisendi S, Piazza F, et al. Dyskeratosis congenita and cancer in mice deficient in ribosomal RNA modification. Science 2003;299:259-262
39. Yoon A, Peng G, Brandenburger Y, et al. Impaired control of IRES-mediated translation in X-linked dyskeratosis congenita. Science 2006;312:902-906
40. Rizos H, McKenzie HA, Ayub AL, et al. Physical and functional interaction of the p14ARF tumor suppressor with ribosomes. J Biol Chem 2006;281:38080-38088
41. Sherr CJ. Divorcing ARF and p53: an unsettled case. Nat Rev Cancer 2006;6:663-673
42. Kelly-Spratt KS, Gurley KE, Yasui Y, Kemp CJ. p19Arf suppresses growth, progression, and metastasis of Hras-driven carcinomas through p53-dependent and -independent pathways. PLoS Biol 2004;2:E242.
43. Ruddell A, Kelly-Spratt KS, Furuya M, Parghi SS, Kemp CJ. p19/Arf and p53 suppress sentinel lymph node lymphangiogenesis and carcinoma metastasis. Oncogene 2008;27:3145-3155
44. Kumar R, Sauroja I, Punnonen K, Jansen C, Hemminki K. Selective deletion of exon 1β of the p19ARF gene in metastatic melanoma cell lines. Genes Chromosomes Cancer 1998;23:273-277
45. McKeller RN, Fowler JL, Cunningham JJ, et al. The Arf tumor suppressor gene promotes hyaloid vascular regression during mouse eye development. Proc Natl Acad Sci U S A 2002;99:3848-3853
46. Silva RL, Thornton JD, Martin AC, et al. Arf-dependent regulation of Pdgf signaling in perivascular cells in the developing mouse eye. EMBO J 2005;24:2803-2814
47. Bernardi R, Guernah I, Jin D, et al. PML inhibits HIF-1α translation and neoangiogenesis through repression of mTOR. Nature 2006; 442:779-785
48. Kuo ML, den Besten W, Bertwistle D, Roussel MF, Sherr CJ. N-terminal polyubiquitination and degradation of the Arf tumor suppressor. Genes Dev 2004;18:1862-1874